AIM ImmunoTech Inc.
AIM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $170 | $202 | $141 | $135 |
| % Growth | -15.8% | 43.3% | 4.4% | – |
| Cost of Goods Sold | $31 | $42 | -$424 | $850 |
| Gross Profit | $139 | $160 | $565 | -$715 |
| % Margin | 81.8% | 79.2% | 400.7% | -529.6% |
| R&D Expenses | $6,197 | $10,925 | $6,990 | $7,672 |
| G&A Expenses | $13,714 | $21,137 | $0 | $8,672 |
| SG&A Expenses | $13,714 | $21,137 | $13,498 | $8,672 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $1,779 |
| Operating Expenses | $19,911 | $32,076 | $20,488 | $18,123 |
| Operating Income | -$19,772 | -$31,916 | -$19,923 | -$18,838 |
| % Margin | -11,630.6% | -15,800% | -14,129.7% | -13,954.1% |
| Other Income/Exp. Net | $2,452 | $2,954 | $478 | -$289 |
| Pre-Tax Income | -$17,320 | -$28,962 | -$19,445 | -$19,127 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17,320 | -$28,962 | -$19,445 | -$19,127 |
| % Margin | -10,188.2% | -14,337.6% | -13,790.8% | -14,168.1% |
| EPS | -0.31 | -0.6 | -0.44 | -0.45 |
| % Growth | 48.3% | -36.4% | 2.2% | – |
| EPS Diluted | -0.31 | -0.6 | -0.44 | -0.45 |
| Weighted Avg Shares Out | 560 | 486 | 480 | 473 |
| Weighted Avg Shares Out Dil | 560 | 486 | 480 | 473 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,192 | $0 | $629 | $0 |
| Interest Expense | $585 | $0 | $0 | $67 |
| Depreciation & Amortization | $246 | $238 | -$424 | $775 |
| EBITDA | -$16,489 | -$28,724 | -$19,869 | -$18,285 |
| % Margin | -9,699.4% | -14,219.8% | -14,091.5% | -13,544.4% |